Comparative Pharmacology
Head-to-head clinical analysis: GO EVAC versus SUTAB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GO EVAC versus SUTAB.
GO-EVAC vs SUTAB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Promotes gastrointestinal motility by acting as a stimulant laxative, likely through direct irritation of the colonic mucosa and possibly via local effects on enteric neurons.
SUTAB is a combination tablet consisting of sodium sulfate, magnesium sulfate, and potassium chloride. It acts as an osmotic laxative by drawing water into the bowel lumen through the osmotic effect of sulfate ions, inducing colonic evacuation. Additionally, magnesium ions enhance this effect by attracting water via osmotic pressure and stimulating the release of cholecystokinin, which promotes peristalsis.
10 mg orally once daily, with or without food.
24 tablets administered as 4 tablets every 15 minutes, total dose of 17.5 g sodium sulfate, 3.13 g magnesium sulfate, and 1.64 g potassium sulfate, orally, with water, the evening before colonoscopy.
None Documented
None Documented
4.5-6 hours in healthy volunteers; prolonged to 10-14 hours in elderly patients and those with moderate renal impairment (CrCl 30-50 mL/min).
Terminal elimination half-life: 6-8 hours in adults with normal renal function; prolonged to 20-40 hours in end-stage renal disease.
Primarily renal; approximately 60% eliminated unchanged in urine within 24 hours, with 20% as metabolites. Biliary/fecal excretion accounts for 15-20%, and the remainder is metabolized via glucuronidation.
Primarily renal excretion (65-75% unchanged) with minor biliary/fecal elimination (<10%). Total body clearance approximates renal blood flow.
Category C
Category C
Osmotic Laxative
Osmotic Laxative